Washington Business Journal | @WBJonline
January 8, 2020, 11:22 AM
The federal government has tapped a local company to help defend against superbugs.
Gaithersburg’s Adaptive Phage Therapeutics Inc. has earned a $10.2 million contract with the Department of Defense to help advance PhageBank, APT’s collection of viruses that target specific pathogens and kill drug-resistant bacteria. The ultimate goal is to make its therapy for drug-resistant infections available to the U.S. military and the public, APT said Wednesday.
A cure for superbugs represents a major unmet need in health care, making this contract “a first step in addressing the worldwide crisis in antibiotic resistant infections,” APT co-founder and CEO Greg Merrill said in a statement to the WBJ.
The funding will support the company’s phase 2 clinical trials for PhageBank, which are expected to generate results in the third quarter of this year.